View Older Stories
-
Insulet launches Omnipod 5 insulin system in Middle East
-
TD Cowen Assumes Insulet Corporation (PODD) at Hold, 'Leading, But Others Catching Up'
-
Barclays Downgrades Insulet Corporation (PODD) to Underweight
-
Barclays Downgrades DexCom (DXCM) to Underweight
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
UBS Reiterates Buy Rating on Insulet Corporation (PODD)
-
Evercore ISI Starts Insulet Corporation (PODD) at Outperform, 'Leading the Tubeless Revolution in Insulin Delivery
-
Bernstein Shares Takeaways From the 5th Annual Diabetes Disruptor Conference
-
Insulet expands Pod recycling program nationwide across US
-
TD Cowen Reiterates Buy Rating on Insulet Corporation (PODD)
-
Insulet Corporation's (PODD) Competitive Moat Is Underappreciated - Analyst
-
Insulet Corporation (PODD) PT Raised to $432 at Canaccord Genuity
-
Insulet Corporation (PODD) PT Raised to $432 at Canaccord Genuity
-
Bernstein on Insulet Corporation (PODD): 'We See Plenty of Upside Potential from Here'
-
Insulet's (PODD) 'Competitive Moat Likely Underappreciated' - UBS
-
Insulet Corporation (PODD) PT Raised to $386 at Leerink Partners
-
Insulet Corporation (PODD) PT Raised to $412 at Truist Securities
-
Insulet Corporation (PODD) PT Raised to $380 at BTIG
-
Insulet Corporation (PODD) PT Raised to $385 at Raymond James
-
Insulet projects 20% revenue growth through 2028 at investor day
-
Buy this stock into tomorrow's Analyst Day: UBS
-
UBS Upgrades Insulet Corporation (PODD) to Buy
-
Insulet Corporation (PODD) PT Raised to $400 at Jefferies
-
BTIG Reiterates Buy Rating on Insulet Corporation (PODD)
-
Insulet (PODD) Tops Q3 EPS by 10c
-
Stifel Resumes Insulet Corporation (PODD) at Buy
-
Insulet Corporation (PODD) PT Raised to $399 at Canaccord Genuity
-
Insulet partners with Pantone to create Omnipod Mango color
-
Truist Securities Reiterates Buy Rating on Insulet Corporation (PODD), CFO transition seed as a modest surprise
-
Insulet Corporation (PODD) PT Raised to $360 at Piper Sandler
-
This medical stock is JPMorgan's Top SMid Cap Pick
-
Piper Sandler on calls with diabetes clinicians
-
Oppenheimer Starts Insulet Corporation (PODD) at Outperform
-
Insulet Corporation (PODD) PT Raised to $300 at Barclays
-
Insulet Corporation (PODD) PT Raised to $350 at RBC Capital
-
Insulet Corporation (PODD) PT Raised to $400 at Bernstein SocGen Group
-
Insulet Corporation (PODD) PT Raised to $353 at Canaccord Genuity
-
Insulet Corporation (PODD) PT Raised to $375 at Jefferies
-
Insulet (PODD) Tops Q2 EPS by 25c
-
Piper Sandler's Key MedTech Takeaways From ADA 2025
-
Truist Securities Starts Insulet Corporation (PODD) at Buy
-
Insulet Corporation (PODD) PT Raised to $379 at TD Cowen After a Stellar 1Q
-
Goldman Sachs Starts Insulet Corporation (PODD) at Buy
-
Insulet Corporation (PODD) PT Raised to $360 at Raymond James
-
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
-
Edwards Lifesciences (EW) Added as Top Pick at Citi, PODD Removed
-
'Insulet Corporation (PODD) is Our Top Pick in Diabetes'; PT Raised to $375 at Bernstein
-
Wolfe Research Upgrades Insulet Corporation (PODD) to Outperform
-
Piper Sandler on Insulet Corporation (PODD): 'Strong Update Across the Board'
-
Insulet Corporation (PODD) PT Raised to $331 at Canaccord Genuity

